6.1
Impella
®
System for Use During Cardiogenic Shock
CARDIAC SHOCK AFTER ACUTE MYOCARDIAL
INFARCTION
SUMMARY OF PRIMARY CLINICAL STUDIES
PROSPECTIVE RANDOMIZED TRIAL: ISAR-SHOCK (FOR IMPELLA 2.5)
To support for safety and effectiveness, data from a small prospective randomized clinical trial
(RCT) was used. The ISAR-SHOCK trial was designed as a prospective, two-center, randomized,
open-label study designed to test whether the Impella 2.5 provides superior hemodynamic
improvement as compared to the standard procedure utilizing IABP for AMICS patients.
The trial was designed to assess the hemodynamic robustness of the Impella 2.5 against IABP
(primary endpoint), as measured by the improvement of cardiac support after device support
initiation. Safety data (survival and adverse events) were also studied (secondary endpoints).
Details of the study design are below.
CLINICAL INCLUSION AND EXCLUSION CRITERIA
Eligible patients were those who presented with cardiogenic shock within 48 hours of an acute
myocardial infarction or suspicion of an acute coronary syndrome. The inclusion and exclusion
criteria are below.
Inclusion Criteria
1.
Systolic Blood Pressure (SBP) < 90 mmHg during angina pectoris and heart rate > 90/
min OR use of catecholamines to maintain SBP> 90 mmHg during angina pectoris;
AND
2.
Signs of end-organ hypoperfusion OR Signs of left ventricular failure (Killip class 3 or 4)
3.
Left Ventricular Ejection Fraction (LVEF)< 30% and Left Ventricular End-Diastolic
Pressure (LVEDP)> 20 mmHg OR
4.
Cardiac Index (CI)< 2.2 l/min/m2 and Pulmonary Capillary Wedge Pressure (PCWP)> 15
mmHg
Exclusion Criteria (Clinical Only)
1.
Age less than 18 years old
2.
Resuscitation for more than 30 minutes
3.
Obstructive, hypertrophic cardiomyopathy
4.
Marginal thrombus in the left ventricle
5.
Subjects with implanted IABP at the point in time of randomization
6.
Mechanical mitral and/or aortic valve, and/or severe valve stenosis
6
C
LIN
IC
A
L E
X
P
E
RI
E
N
C
E
Summary of Contents for Impella 2.5
Page 4: ......
Page 8: ......
Page 10: ......
Page 12: ......
Page 15: ...2 WARNINGS AND CAUTIONS WARNINGS 2 1 CAUTIONS 2 3...
Page 16: ......
Page 22: ......
Page 38: ......
Page 40: ......
Page 108: ......
Page 171: ......
Page 173: ......
Page 181: ......
Page 183: ......
Page 201: ......
Page 203: ......
Page 205: ......
Page 210: ...INDEX TBD...